Cargando…

Predicting Therapeutic Response to Unfractionated Heparin Therapy: Machine Learning Approach

BACKGROUND: Unfractionated heparin (UFH) is an anticoagulant drug that is considered a high-risk medication because an excessive dose can cause bleeding, whereas an insufficient dose can lead to a recurrent embolic event. Therapeutic response to the initiation of intravenous UFH is monitored using a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abdel-Hafez, Ahmad, Scott, Ian A, Falconer, Nazanin, Canaris, Stephen, Bonilla, Oscar, Marxen, Sven, Van Garderen, Aaron, Barras, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	JMIR Publications 2022
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9531006/ https://www.ncbi.nlm.nih.gov/pubmed/35993617 http://dx.doi.org/10.2196/34533

Ejemplares similares

Impact of COVID-19 on monitoring of therapeutic unfractionated heparin
por: Adie, Sarah K., et al.
Publicado: (2020)

Unfractionated and low molecular weight heparin
por: Lima, Marcelo, et al.
Publicado: (2014)

The efficacy and safety of low-molecular-weight heparin and unfractionated heparin in the treatment of cerebral venous sinus thrombosis
por: Afshari, Daryoush, et al.
Publicado: (2015)

Unfractionated heparin and mechanical thromboprophylaxis in hip arthroplasty
por: Garcia, Flávio Luís, et al.
Publicado: (2015)

Alternatives to standard unfractionated heparin for pediatric hemodialysis treatments
por: Davenport, Andrew
Publicado: (2012)

Quantitative Analysis of Impurities in Unfractionated Heparin of Bovine Origin
por: Workman, Wesley E., et al.
Publicado: (2020)

Differential Neutralization of Unfractionated Heparin and Enoxaparin by Andexanet Alfa
por: Lewis, Joseph, et al.
Publicado: (2022)

Resistance to unfractionated heparin in the ICU: evaluation and management options
por: Levy, Jerrold H., et al.
Publicado: (2023)

Establishing the heparin therapeutic range using aPTT and anti-Xa measurements for monitoring unfractionated heparin therapy
por: Byun, Jung-Hyun, et al.
Publicado: (2016)

Inhibition of Gastric Acid Secretion by Unfractionated and Low Molecular Weight Heparins in the Rat
por: Abdel Salam, Omar M.E., et al.
Publicado: (2006)

Time in the Therapeutic Range for Assessing Anticoagulation Quality in Patients Receiving Continuous Unfractionated Heparin
por: Ting, Clara, et al.
Publicado: (2018)

Management of therapeutic unfractionated heparin in COVID‐19 patients: A retrospective cohort study
por: Weeks, Lachelle D., et al.
Publicado: (2021)

Unfractionated heparin in acute chest syndrome: a pilot feasibility randomized controlled trial of unfractionated heparin vs. standard of care in acute chest syndrome
por: Seaman, Craig D., et al.
Publicado: (2020)

Outcomes of thromboprophylaxis with enoxaparin vs. unfractionated heparin in medical inpatients
por: McGarry, Lisa J, et al.
Publicado: (2006)

Opposition: Unfractionated heparin should no longer be used in the catheterization laboratory
por: Kim, Moo Hyun, et al.
Publicado: (2014)

Low-Molecular-Weight Heparin and Unfractionated Heparin Decrease Th-1, 2, and 17 Expressions
por: Huang, Jing-Ning, et al.
Publicado: (2014)

Temporality of heparin-induced antibodies: a retrospective study in outpatients undergoing hemodialysis on unfractionated heparin
por: Maharaj, Satish, et al.
Publicado: (2018)

Low-molecular-weight heparin compared with unfractionated heparin in critically ill COVID-19 patients
por: Volteas, Panagiotis, et al.
Publicado: (2022)

Distinct Effects of Unfractionated Heparin versus Bivalirudin on Circulating Angiogenic Peptides
por: Kapur, Navin K., et al.
Publicado: (2012)

Unfractionated Heparin Promotes Osteoclast Formation in Vitro by Inhibiting Osteoprotegerin Activity
por: Li, Binghan, et al.
Publicado: (2016)

Nonclinical Evaluation of Novel Cationically Modified Polysaccharide Antidotes for Unfractionated Heparin
por: Kalaska, Bartlomiej, et al.
Publicado: (2015)

Individual variation in unfractionated heparin dosing after pediatric cardiac surgery
por: Hikino, Keiko, et al.
Publicado: (2020)

Validation of high concentrated thrombin time assay for unfractionated heparin monitoring
por: Apipongrat, Dollapak, et al.
Publicado: (2022)

Effectiveness, safety, and costs of thromboprophylaxis with enoxaparin or unfractionated heparin in inpatients with obesity
por: Amin, Alpesh, et al.
Publicado: (2023)

Evaluation of Antifactor-Xa Heparin Assay and Activated Partial Thromboplastin Time Values in Patients on Therapeutic Continuous Infusion Unfractionated Heparin Therapy
por: McLaughlin, Kevin, et al.
Publicado: (2019)

A comparative study of dalteparin and unfractionated heparin in patients with unstable angina pectoris
por: Amane, Hanmant S., et al.
Publicado: (2011)

Cost-utility of enoxaparin compared with unfractionated heparin in unstable coronary artery disease
por: Nicholson, Tricia, et al.
Publicado: (2001)

Impact of nebulized unfractionated heparin and N-acetylcysteine in management of smoke inhalation injury
por: Elamin, E, et al.
Publicado: (2009)

Pharmacokinetic model of unfractionated heparin during and after cardiopulmonary bypass in cardiac surgery
por: Jia, Zaishen, et al.
Publicado: (2015)

Unfractionated heparin displaces sFlt-1 from the placental extracellular matrix
por: Moore, Kyle H., et al.
Publicado: (2020)

Unfractionated Heparin Improves the Intestinal Microcirculation in a Canine Septic Shock Model
por: Zhang, Heng, et al.
Publicado: (2021)

Safety of low-molecular-weight heparin compared to unfractionated heparin in hemodialysis: a systematic review and meta-analysis
por: Lazrak, Hind Harrak, et al.
Publicado: (2017)

A direct comparison of prophylactic low-molecular-weight heparin versus unfractionated heparin in neurosurgery: A meta-analysis
por: Macki, Mohamed, et al.
Publicado: (2019)

Unfractionated heparin or low-molecular-weight heparin for venous thromboembolism prophylaxis after hepatic resection: A meta-analysis
por: Zhang, Wentao, et al.
Publicado: (2022)

Rates of clinically apparent heparin-induced thrombocytopenia for unfractionated heparin vs. low molecular weight heparin in non-surgical patients are low and similar
por: Locke, Charles FS, et al.
Publicado: (2005)

Unfractionated heparin inhibits live wild type SARS‐CoV‐2 cell infectivity at therapeutically relevant concentrations
por: Tree, Julia A., et al.
Publicado: (2020)

Effect of unfractionated and low molecular weight heparin on microcirculatory antithrombin effects during endotoxemia
por: Hoffmann, JN, et al.
Publicado: (2002)

Effect of a Direct Thrombin Inhibitor Compared with Dalteparin and Unfractionated Heparin on Human Osteoblasts
por: Winkler, Tobias, et al.
Publicado: (2011)

Unfractionated Heparin in SARS-CoV-2 Pneumonia: Ischemic Stroke Case Report
por: Efendizade, Aslan, et al.
Publicado: (2020)

Monitoring of Unfractionated Heparin in Severe COVID-19: An Observational Study of Patients on CRRT and ECMO
por: Streng, Alexander S., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_the2ofa0mlkr172n6tgja2v78u